1. Academic Validation
  2. Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding

Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding

  • J Med Chem. 2006 Jun 29;49(13):3832-49. doi: 10.1021/jm0601001.
George S Sheppard 1 Jieyi Wang Megumi Kawai Steve D Fidanze Nwe Y BaMaung Scott A Erickson David M Barnes Jason S Tedrow Lawrence Kolaczkowski Anil Vasudevan David C Park Gary T Wang William J Sanders Robert A Mantei Fabio Palazzo Lora Tucker-Garcia Pingping Lou Qian Zhang Chang H Park Ki H Kim Andrew Petros Edward Olejniczak David Nettesheim Phillip Hajduk Jack Henkin Richard Lesniewski Steven K Davidsen Randy L Bell
Affiliations

Affiliation

  • 1 Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Department R47A, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA. george.s.sheppard@abbott.com
Abstract

Methionine aminopeptidase-2 (MetAP2) is a novel target for Cancer therapy. As part of an effort to discover orally active reversible inhibitors of MetAP2, a series of anthranilic acid sulfonamides with micromolar affinities for human MetAP2 were identified using affinity selection by mass spectrometry (ASMS) screening. These micromolar hits were rapidly improved to nanomolar leads on the basis of insights from protein crystallography; however, the compounds displayed extensive binding to human serum albumin and had limited activity in cellular assays. Modifications based on structural information on the binding of lead compounds to both MetAP2 and domain III of albumin allowed the identification of compounds with significant improvements in both parameters, which showed good cellular activity in both proliferation and methionine processing assays.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-182419
    MetAP-2抑制剂